Postnatal lung responses and surfactant function after fetal or maternal corticosteroid treatment.
To evaluate the effect of dose and route of administration of betamethasone on subsequent postnatal lung function, pregnant ewes were randomized at 127 days gestation to receive maternal or fetal intramuscular doses of 0.2 or 0.5 mg/kg body wt betamethasone or saline. At delivery 24 h later, preterm lambs were treated with surfactant and ventilated for 4 h. The lambs exposed to 0.5 mg/kg betamethasone by either the maternal or fetal route had higher Po2 values, lung volumes, dynamic compliances, and ventilatory efficiency indexes, as well as lower ventilatory pressure requirements, than did control animals (P < 0.05). There were no consistent improvements in postnatal lung function for the 0.2 mg/kg dose given to the fetus or ewe. However, measurements of radiolabeled protein in the total lung were decreased in all treatment groups (P < 0.01). Surfactant that was recovered from all groups of lambs and fractionated to isolate the large-aggregate fraction improved lung volumes in preterm rabbits to a greater degree than the surfactant used to treat the lambs (P < 0.05). Surfactant recovered from both groups treated with 0.5 mg/kg betamethasone was less sensitive to inactivation by plasma than was surfactant from the 0.2 mg/kg groups or the controls (P < 0.01). Fetal or maternal treatment with 0.5 mg/kg betamethasone improved postnatal lung function and increased the resistance of surfactant to inactivation.
Rebello
C M
CM
Department of Pediatrics, Harbor-UCLA Medical Center, University of California, Los Angeles School of Medicine, Torrance 90509, USA.
Ikegami
M
M
Polk
D H
DH
Jobe
A H
AH
D000305:Adrenal Cortex Hormones / Q000494:pharmacology*; D000818:Animals; D000831:Animals, Newborn; D001623:Betamethasone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D008168:Lung / Q000187:drug effects*; D018811:Maternal Exposure; D011247:Pregnancy; D011312:Pressure; D011817:Rabbits; D012756:Sheep; D013501:Surface-Active Agents
D000305:Adrenal Cortex Hormones; D013501:Surface-Active Agents; D001623:Betamethasone